Vise Technologies Inc. Takes Position in Icon Plc $ICLR

Vise Technologies Inc. purchased a new position in shares of Icon Plc (NASDAQ:ICLR) during the fourth quarter, Holdings Channel reports. The firm purchased 3,632 shares of the medical research company’s stock, valued at approximately $662,000.

Other large investors have also added to or reduced their stakes in the company. Toth Financial Advisory Corp acquired a new stake in Icon during the fourth quarter worth approximately $27,000. Ameriflex Group Inc. acquired a new stake in Icon during the third quarter worth approximately $33,000. Johnson Financial Group Inc. acquired a new stake in Icon during the third quarter worth approximately $71,000. Quadrant Capital Group LLC acquired a new stake in Icon during the third quarter worth approximately $78,000. Finally, Geneos Wealth Management Inc. grew its position in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after buying an additional 56 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Trading Down 4.8%

NASDAQ ICLR opened at $144.59 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a market cap of $11.07 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 11.99 and a beta of 1.26. The business’s fifty day moving average is $120.28 and its 200 day moving average is $140.53.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, June 10th. The medical research company reported $2.52 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.05. Icon had a return on equity of 9.50% and a net margin of 5.98%.The company had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $1.99 billion. During the same quarter last year, the business posted $3.43 EPS. Icon’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, sell-side analysts expect that Icon Plc will post 9.74 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ICLR shares. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Bank of America reissued an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Citigroup increased their price target on Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, May 29th. Leerink Partners set a $145.00 price target on Icon in a research report on Thursday, May 28th. Finally, Robert W. Baird set a $119.00 price target on Icon in a research report on Friday, February 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $156.44.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.